Health clinics, designed for innovation
Evidence-based healthcare has always been a big part of our business at Emyria. In this environment, we can make the most impact on people; measure our impact; and importantly, use our frontline learning with patients to inform innovation.
As our business has matured, we have purposefully migrated towards a clinical service model that is aligned with our motivation to move the dial in mental health, in a profitable, impactful and scalable healthcare design.
Put simply – our healthcare business model is the epicentre of what allows us to evaluate and improve innovative treatments like psychedelic-assisted therapies in a safe and regulatory compliant and commercially viable way.
How we care
We are working methodically to test and refine our healthcare models before we expand. Our lead operations are in Western Australia. This is where we test work-flow models that we believe will allow us to scale around the country and beyond.
Our unique clinical resources comprise:
Dedicated facilities with multiple consulting rooms
Opt-in patient data and state-of-the-art data research platform, Palantir Foundry
Ethics-endorsed care models
20+ trained clinicians
Emyria clinics, core intellectual property (IP)
The Therapeutic Goods Association (TGA) reclassified psychedelic substances and psilocybin from July 2023. The reclassification permits the prescribing by specifically authorised psychiatrists of MDMA for the treatment of post-traumatic stress disorder and psilocybin for treatment-resistant depression. The reclassification means Emyria and Australia are potentially years ahead of other jurisdictions like the United States in respect of the potential to use those products to treat patients.
We are disciplined in the way we deliver these novel treatments – and the Emyria team is deeply committed to creating standardised, safe, effective, scalable and commercially viable care programs to do so.
Psychedelic-assisted therapies have already shown promise in Phase III trials; but modern mental health systems have not adapted to support the necessary high-touchpoint, high-cost mental health therapy model which they demand.
Emyria already possesses the core competencies and experience to lead this work, across the most important elements of drug supply management; data gathering and analysis; care model design; and implementation on the frontline.
We are initially targeting PTSD with a strategic plan to continuously measure, learn and broaden treatment offerings to adjacent mental health conditions.
Our end goal is to lead an international network of advanced, multidisciplinary mental health clinics that are thriving financially and making a tangible patient impact – by offering truly personalised and effective mental health programs.
MENTAL HEALTH DESPERATELY NEEDS NEW INNOVATION
Prevalence of mental ill health in Australia1
…more than 1 million Australians unable to access the care they need.
On the supply side, mental health services are struggling to meet the rising demand.
There is an urgent workforce shortage of trained mental health professionals, including psychiatrists, psychologists, mental health nurses, occupational therapists and social workers.”
Sources:
1. BlackDog Institute Pre-Budget Submission January 2023. Note: BlackDog Institute has not provided its consent to be named on this website.